One man's brain tumor stayed stable for over seven years on nivolumab
Original title: Exceptional Long-Term Disease Stability Under Nivolumab in Recurrent High-Grade Glioma: A Case Report.
How far along is this research?
- Lab cells
- Animals
- Review
- Tested in people
This was tested in people. That is the most reliable kind of research we share.
This is a report on one patient, not a study, and the drug is not approved for this brain tumor.
The short version
In one patient, a drug that wakes up the immune system kept a fast-growing brain tumor from growing again for more than seven years.
What was studied. Doctors reported on one patient, a 30-year-old man with a high-grade glioma: A tumor that starts in the glial cells, the support cells of the brain and spinal cord. Gliomas are graded 1 to 4 by how fast they tend to grow. See the glossary in the right side of his brain. He had surgeries, radiation, and chemotherapy drugs, but the tumor kept coming back. With no standard options left, he was given nivolumab off label starting in November 2018.
What they found. Scans over time showed the tumor stayed stable. The most recent scan, in March 2026, showed it was still stable more than seven years after the drug was started. He handled the drug well. His only side effect was mild joint pain from the immune system. He still lives independently, with mild lasting weakness on one side.
What this means, and what it doesn't
What it could mean: For a few people, this type of immune drug may hold a high-grade glioma: A tumor that starts in the glial cells, the support cells of the brain and spinal cord. Gliomas are graded 1 to 4 by how fast they tend to grow. See the glossary steady for a long time. His tumor had certain traits, an IDH1 R132H change and a silenced MGMT gene. He had also stopped steroids before starting the drug. Doctors think these things may have helped, but they do not know for sure. If you want to know whether an immune drug fits your situation, that is a question for your own care team.
What it doesn't mean: This is a report about one single patient. It is not a study. Nothing here proves the drug works for other people. In fact, these immune drugs have not helped high-grade glioma: A tumor that starts in the glial cells, the support cells of the brain and spinal cord. Gliomas are graded 1 to 4 by how fast they tend to grow. See the glossary patients as a whole in larger studies. Nivolumab was used off label here, which means it is not an approved treatment for this tumor. This is not a cure, and it is not a promise that anyone else will get the same result.
Source: PubMed, June 16, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.